This page shows the latest Orfadin news and features for those working in and with pharma, biotech and healthcare.
In July the European Commission approved an oral suspension formulation of Orfadin (nitisinone), which treats the rare - and potentially fatal - genetic disease Hereditary Tyrosinaemia type-1 (HT-1). ... More recently the FDA this week began its review
Expandstreatment options for rare genetic disease HT-1. The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone). ... An oral suspension of Orfadin for paediatric use will facilitate
disease. Although there is currently no cure for AKU, Swedish Orphan Biovitrum's tyrosinaemia treatment Orfadin (nitisinone) is used off-label to treat AKU and is expected to enter phase III
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...